Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 déc. 2025 10h39 HE | Source: Brain & Behavior Research Foundation

What Can Light Show Us About Brain Activity? Examining Early Neural and Behavioral Predictors of Childhood ADHD

New York, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Attention-deficit/hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder, affecting roughly 1 in 10 children. It can impact peer and...
24 nov. 2025 14h39 HE | Source: Yoffe Therapy

Jeanette Yoffe Publishes "The Traumatized and At-Risk Youth Toolbox," Her Newest Guidebook With Over 160 Attachment-Informed Interventions for Working with Kids and Families in Foster Care and Beyond

Jeanette Yoffe, M.A., LMFT has authored The Traumatized and At-Risk Youth Toolbox, with 160 interventions for traumatized and at-risk children
18 nov. 2025 11h00 HE | Source: NeuroSigma, Inc.

NeuroSigma Launches Next-Generation Monarch Device for Pediatric ADHD After Successful Pilot Program

LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced the successful completion of its pilot commercialization program for the...
13 nov. 2025 08h00 HE | Source: Cingulate Inc.

Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) --...
10 nov. 2025 08h00 HE | Source: Cingulate Inc.

Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate’s transition toward commercialization pending FDA approval Company also strengthens its cash...
03 nov. 2025 11h00 HE | Source: NeuroSigma, Inc.

NeuroSigma Announces New Publication Showing Real-Time Effects of External Trigeminal Nerve Stimulation (eTNS) on Brain Activity

LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced a new publication in the journal Neuromodulation: Technology at the...
29 oct. 2025 11h00 HE | Source: Plum Tree Psychology

Plum Tree Launches New Chronic Illness Therapy Program

Plum Tree Psychology a leading behavioral-health practice in the Fox Valley, has announced the launch of its new Chronic Illness Therapy Program.
28 oct. 2025 08h00 HE | Source: Cingulate Inc.

Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control

KANSAS CITY, Kan., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products...
23 oct. 2025 16h45 HE | Source: Cingulate Inc.

Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

KANSAS CITY, Kan., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products...
15 oct. 2025 04h30 HE | Source: Custom Market Insights

[Latest] Global Biofeedback Instrument Market Size/Share Worth USD 340 Million by 2034 at a 6.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Biofeedback Instrument Market Size, Trends and Insights By Product Type (EMG...

Page suivante